Companies to develop new tumour marker:
This article was originally published in Clinica
Executive Summary
Canada's York Medical and its partner Centre for Molecular Immunology (CIM) are to develop a monoclonal antibody for diagnosing cancers of epithelial origin, such as those in the head, neck, breast and lung. The product, DiaCIM, will use the human version of the monoclonal antibody hR3 to identify cancers that over-express epidermal growth factor receptor (EGF-r), which is associated with the continuing growth of cancer cells, metastatic spread and poor prognosis. DiaCIM could also help identify patients who may respond to therapeutic versions of hR3, said Mississauga, Ontario-based York Medical.
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.